Targeting IL-17RB and MCT 2 to treat breast cancer may be possible

Targeting IL-17RB and MCT 2 to treat breast cancer may be possible

The Genetic Materials Research Center at Taiwan’s Academia Sinica reports two new possibilities in treating breast cancer by developing an antibody of the IL-17RB gene and medication targeting the MCT 2 gene.

When breast tumor cells enter the lymph nodes, the TGF-beta 1 factor, a polypeptide of TGF (transforming growth factor Beta of the super family of cytokines), secreted by  Tregs (regulatory T cells) will activate the IL-17RB (Interleukin 17 Receptor B) cells and help the growth of the breast tumor cells.  The secretion of the TGF-beta 1 factor will also increase toxicity of the breast cancer cells and increase the possibility of migratory transfer of the cancer cells.  Among breast cancer patients, 20% to 25% carry the IL-17RB gene.

The research team also discovered that lipocytes (adipocytes) also promote malignant growth of breast tumors with monocarboxylate transporter 2 (MCT 2) expression via Beta-hydroxybutyrate.  In future, it may be possible to develop medications targeting the MCT 2 in breast cancer treatment.


About masterchensays

Victor Chen, herbalist, alternative healthcare lecturer, Chinese affairs analyst, retired journalist
This entry was posted in Uncategorized. Bookmark the permalink.